Endocrine effects of Toremifene(Fareston) and Leuprolide(Leuplin) therapy in premenopausal breast cancer patients

Trial Profile

Endocrine effects of Toremifene(Fareston) and Leuprolide(Leuplin) therapy in premenopausal breast cancer patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Leuprorelin (Primary) ; Toremifene (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 28 Jul 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.
    • 20 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top